SCHEMBL17834773

SCHEMBL17834773

CCCCCc1ccc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(C)(C)C)s5)C(=O)N[C@H](C)C(=O)O)cc4)nc3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 4/20 0.39
ANPEP P15144 2/20 0.39
RARB P10826 2/20 0.39
KIFC1 Q9BW19 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SRC P12931 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DGAT1 O75907 1/20 0.36
MMP3 P08254 1/20 0.36
ACE P12821 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16306215 0.99 RARB (0.40) MMEANPEPRARBKIFC1KDM4E
SCHEMBL17834846 0.98 MME (0.40) MMEANPEPRARBKIFC1L3MBTL1
SCHEMBL17834848 0.95 KIFC1 (0.41) MMEANPEPKIFC1L3MBTL1
SCHEMBL17834902 0.92 MME (0.41) MMEANPEPKIFC1L3MBTL1
SCHEMBL16306224 0.92 MME (0.46) MMEANPEPACECPA1ACE2
SCHEMBL17834747 0.92 ITGB1 (0.44)
SCHEMBL16305971 0.92 ITGB1 (0.44)
SCHEMBL16306233 0.92 MME (0.38) MMEANPEPKIFC1L3MBTL1ACE
SCHEMBL16305982 0.91 ITGB1 (0.41) MMEANPEP
SCHEMBL17834572 0.91 MME (0.46) MMEANPEPACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MME 796/4885ANPEP 305/4885RARB 1094/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MME 796/4885ANPEP 305/4885RARB 1094/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR MME 919/4885ANPEP 407/4885RARB 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.